Literature DB >> 8224935

Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.

U H Steinhorst1, D L Hatchell, E P Chen, R Machemer.   

Abstract

Daunomycin is a potent antiproliferative agent which has been shown to prevent experimental proliferative vitreoretinopathy. However, toxic effects on the rabbit retina have been reported even for the lowest effective doses. In a previous report we demonstrated that subdivided doses rather than single doses of daunomycin improves the efficacy in prevention of experimental proliferative vitreoretinopathy. To evaluate whether dose subdivision would also have an alleviating effect on drug toxicity, we administered 15 nmol daunomycin in doses of 10 nmol and 5 nmol 4 h apart into the vitreous cavity of rabbit eyes which had previously undergone vitreous gas compression. All contralateral eyes received sham treatment. Simultaneous electroretinographic recordings from both eyes on days 0, 3, 7, and 14 demonstrated a significant b-wave decline in drug-exposed eyes. Morphological studies on these eyes revealed no retinal damage. Our findings suggest that dose subdivision does not eliminate the retinal toxicity of daunomycin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224935     DOI: 10.1007/bf00936524

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  16 in total

1.  Control of experimental massive periretinal proliferation by daunomycin: dose-response relation.

Authors:  P Wiedemann; M Kirmani; M Santana; N Sorgente; S J Ryan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

2.  Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy.

Authors:  P Wiedemann; C Leinung; R D Hilgers; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

3.  Naka-Rushton equation parameters in electroretinogram analysis of daunomycin effects on retinal function.

Authors:  D V Gangadhar; B M Wolf; H L Tanenbaum
Journal:  Doc Ophthalmol       Date:  1989-05       Impact factor: 2.379

4.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

5.  A refined experimental model for proliferative vitreoretinopathy.

Authors:  D B Chandler; F A Quansah; T Hida; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

6.  Gas-mediated vitreous compression: an experimental alternative to mechanized vitrectomy.

Authors:  R J Thresher; M Ehrenberg; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1984       Impact factor: 3.117

7.  Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit.

Authors:  M Santana; P Wiedemann; M Kirmani; D S Minckler; R Patterson; N Sorgente; S J Ryan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1984       Impact factor: 3.117

8.  Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo.

Authors:  P Wiedemann; N Sorgente; C Bekhor; R Patterson; T Tran; S J Ryan
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-05       Impact factor: 4.799

9.  Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy.

Authors:  P Wiedemann; K Lemmen; R Schmiedl; K Heimann
Journal:  Am J Ophthalmol       Date:  1987-07-15       Impact factor: 5.258

10.  The clearance of intravitreal triamcinolone acetonide.

Authors:  R H Schindler; D Chandler; R Thresher; R Machemer
Journal:  Am J Ophthalmol       Date:  1982-04       Impact factor: 5.258

View more
  2 in total

1.  Presumed Chemotherapy-Induced Optic Neuropathy and Maculopathy: A Case Report.

Authors:  David J Mathew; Anupriya Arthur; Sheeja Susan John
Journal:  Open Ophthalmol J       Date:  2017-09-30

2.  The impact of octreotide in experimental proliferative vitreoretinopathy.

Authors:  Ozge Evren; Burak Turgut; Ulku Celiker; Kadir Ates
Journal:  Indian J Ophthalmol       Date:  2013-03       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.